Dyslipidemia Drugs Market at a CAGR of -10.3% from 2015 to 2023
Dyslipidemia is a chronic metabolic disease, characterized by abnormal amount of low density lipoprotein, high density lipoprotein and triglyceride levels. Abnormal lipid level is also one of the major risk factor for the cardiovascular diseases such as atherosclerosis, hypertension and others. The range of therapeutics which includes statins, bile acid resins, cholesterol absorption inhibitors, fibric acid derivatives, omega-3 fatty acid derivatives and niacins are used for the treatment and mitigation of dyslipidemia disorder. Additionally, combination therapies such as statin and...
View full press release